MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

CureVac NV

Closed

3.25 2.2

Overview

Share price change

24h

Current

Min

3.16

Max

3.3

Key metrics

By Trading Economics

Income

-409M

-39M

Sales

-479M

14M

P/E

Sector Avg

3.915

57.333

EPS

-0.156

Profit margin

-266.508

Employees

825

EBITDA

-410M

-35M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+62.07% upside

Dividends

By Dow Jones

Next Earnings

22 maj 2025

Market Stats

By TradingEconomics

Market Cap

-14M

723M

Previous open

1.05

Previous close

3.25

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

CureVac NV Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 lip 2024, 09:14 UTC

Acquisitions, Mergers, Takeovers

GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update

3 lip 2024, 14:18 UTC

Acquisitions, Mergers, Takeovers

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

3 lip 2024, 09:38 UTC

Market Talk

CureVac Shares Surge Premarket After Expanded Licensing Deal With GSK -- Market Talk

Peer Comparison

Price change

CureVac NV Forecast

Price Target

By TipRanks

62.07% upside

12 Months Forecast

Average 5.17 USD  62.07%

High 10 USD

Low 2.5 USD

Based on 3 Wall Street analysts offering 12 month price targets forCureVac NV - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

1

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

3.0628 / 3.19Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About CureVac NV

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.